Shares of Bliss GVS Pharma Limited touched a fresh 52-week high of Rs 446.90 on 3 June on NSE, after the company disclosed it had received a WHO inspection closure report confirming its Palghar East facility in Maharashtra meets Good Manufacturing Practice standards.

The WHO update is the second major piece of news for Bliss GVS in recent weeks. 

In May, specialty chemicals firm Anupam Rasayan India announced plans to acquire up to 74.2% stake in the company.

Under that deal, Anupam Rasayan will first buy a 43.3% stake directly at Rs 299 per share, for a total of Rs 1,369.51 crore. It will then make an open offer to public shareholders to pick up an additional 26% at the same price. 

Anupam Rasayan said Rs 300 crore of the acquisition financing would come through a term loan, with the balance funded through a non-controlling equity instrument.

It is a stamp of approval from the World Health Organization confirming that the factory follows international quality standards for making medicines. 

For a pharma company that sells to markets across Africa, Asia and Latin America, this kind of clearance matters for maintaining export relationships and winning new supply contracts.

Bliss GVS makes formulations including suppositories, capsules, tablets and injectables. 

The company holds EU-GMP certification and has approvals from both the USFDA and WHO across its Maharashtra and Daman facilities.

At 11:32 am on 3 June, BLISSGVS was trading up 0.99% at Rs 438.75 on NSE, off the session high of Rs 446.90. The stock’s 52-week low stands at Rs 118.00, touched on 10 November 2025.

Unlock profitable opportunities every day! Tradz by EquityPandit provides actionable intraday trading signals for stocks and futures. Don’t miss out – download Tradz by EquityPandit and start winning now!